Login / Signup

Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.

Manmeet S AhluwaliaAhmad OzairJan DrappatzXiaobu YeSen PengMatthew LeeSanhita RathHarshil D DhruvYue HaoMichael E BerensTobias WalbertMatthias HoldhoffGlenn J LesserTimothy F CloughesyAndrew E SloanNaoko TakebeMarta CouceDavid M PeereboomLouis Burt NaborsPatrick Yung WenStuart A GrossmanLisa R Rogers
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These findings confirm the safety and feasibility of TRC102+TMZ in patients with rGBM. They also warrant further evaluation of combination therapy in biomarker-enriched trials enrolling GBM patients with baseline hyperactivated DDR pathways.
Keyphrases
  • combination therapy
  • phase iii
  • study protocol
  • clinical trial
  • phase ii
  • newly diagnosed
  • open label
  • double blind